Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Animals
Cell Line, Tumor
Cell Transformation, Neoplastic
/ drug effects
Female
Forkhead Box Protein O1
/ metabolism
Fusion Proteins, bcr-abl
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Interleukin-7
/ pharmacology
Interleukin-7 Receptor alpha Subunit
/ antagonists & inhibitors
Mice
Mice, Mutant Strains
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
Protein Kinase Inhibitors
/ pharmacology
Receptors, CXCR4
/ genetics
Signal Transduction
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 06 2020
24 06 2020
Historique:
received:
08
08
2019
accepted:
29
05
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Ph
Identifiants
pubmed: 32581241
doi: 10.1038/s41467-020-16927-w
pii: 10.1038/s41467-020-16927-w
pmc: PMC7314847
doi:
Substances chimiques
CXCR4 protein, human
0
FOXO1 protein, human
0
Forkhead Box Protein O1
0
IL7R protein, human
0
Interleukin-7
0
Interleukin-7 Receptor alpha Subunit
0
Protein Kinase Inhibitors
0
Receptors, CXCR4
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3194Subventions
Organisme : NCI NIH HHS
ID : R01 CA213138
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA157644
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197628
Pays : United States
Organisme : Chief Scientist Office
ID : ETM/374
Pays : United Kingdom
Organisme : Howard Hughes Medical Institute
Pays : United States
Références
Ribeiro, R. C. et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70, 948–953 (1987).
pubmed: 3307953
doi: 10.1182/blood.V70.4.948.948
Arico, M. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342, 998–1006 (2000).
pubmed: 10749961
doi: 10.1056/NEJM200004063421402
Schultz, K. R. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia 28, 1467–1471 (2014).
pubmed: 24441288
pmcid: 4282929
doi: 10.1038/leu.2014.30
Alsadeq, A. et al. IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 132, 1614–1617 (2018).
Mazzucchelli, R. & Durum, S. K. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7, 144–154 (2007).
pubmed: 17259970
doi: 10.1038/nri2023
Park, L. S. et al. Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor. J. Exp. Med. 192, 659–670 (2000).
pubmed: 10974032
pmcid: 2193276
doi: 10.1084/jem.192.5.659
Geng, H. et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409–425 (2015).
pubmed: 25759025
pmcid: 4618684
doi: 10.1016/j.ccell.2015.02.003
Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115, 1006–1017 (2010).
pubmed: 19965641
doi: 10.1182/blood-2009-08-235408
Sasson, S. C. et al. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine 50, 58–68 (2010).
pubmed: 20060740
doi: 10.1016/j.cyto.2009.12.001
Mullighan, C. G. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Educ. Program 2012, 389–396 (2012).
Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901–908 (2011).
pubmed: 21536738
pmcid: 3092356
doi: 10.1084/jem.20110580
Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 10, 176–184 (2009).
pubmed: 19136962
pmcid: 2856471
doi: 10.1038/ni.1689
Herzog, S., Reth, M. & Jumaa, H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9, 195–205 (2009).
pubmed: 19240758
doi: 10.1038/nri2491
Herzog, S. et al. SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat. Immunol. 9, 623–631 (2008).
pubmed: 18488031
doi: 10.1038/ni.1616
Guo, F. et al. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 35, 816–826 (2016).
pubmed: 25961926
doi: 10.1038/onc.2015.139
van den Berk, L. C. et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 166, 240–249 (2014).
pubmed: 24697337
doi: 10.1111/bjh.12883
Hayashi, S. et al. Stepwise progression of B lineage differentiation supported by interleukin 7 and other stromal cell molecules. J. Exp. Med. 171, 1683–1695 (1990).
pubmed: 2332734
doi: 10.1084/jem.171.5.1683
Nagasawa, T. CXCL12/SDF-1 and CXCR4. Front. Immunol. 6, 301 (2015).
pubmed: 26124757
pmcid: 4464259
doi: 10.3389/fimmu.2015.00301
Haferlach, T. et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 28, 2529–2537 (2010).
pubmed: 20406941
pmcid: 5569671
doi: 10.1200/JCO.2009.23.4732
Li, J. F. et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc. Natl Acad. Sci. USA 115, E11711–E11720 (2018).
pubmed: 30487223
doi: 10.1073/pnas.1814397115
Jacobs, S. R., Michalek, R. D. & Rathmell, J. C. IL-7 is essential for homeostatic control of T cell metabolism in vivo. J. Immunol. 184, 3461–3469 (2010).
pubmed: 20194717
pmcid: 2980949
doi: 10.4049/jimmunol.0902593
Peschon, J. J. et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 1955–1960 (1994).
pubmed: 7964471
doi: 10.1084/jem.180.5.1955
Nie, Y. et al. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med. 200, 1145–1156 (2004).
pubmed: 15520246
pmcid: 2211858
doi: 10.1084/jem.20041185
Ptasznik, A. et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 196, 667–678 (2002).
pubmed: 12208881
pmcid: 2193994
doi: 10.1084/jem.20020519
Becker, M., Hobeika, E., Jumaa, H., Reth, M. & Maity, P. C. CXCR4 signaling and function require the expression of the IgD-class B-cell antigen receptor. Proc. Natl Acad. Sci. USA 114, 5231–5236 (2017).
pubmed: 28461496
doi: 10.1073/pnas.1621512114
Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399–401 (2004).
pubmed: 15256671
doi: 10.1126/science.1099480
Flemming, A., Brummer, T., Reth, M. & Jumaa, H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat. Immunol. 4, 38–43 (2003).
pubmed: 12436112
doi: 10.1038/ni862
Moriguchi, M. et al. CXCL12 signaling is independent of Jak2 and Jak3. J. Biol. Chem. 280, 17408–17414 (2005).
pubmed: 15611059
doi: 10.1074/jbc.M414219200
Nosaka, T. & Kitamura, T. Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. Int J. Hematol. 71, 309–319 (2000).
pubmed: 10905049
Goetz, C. A., Harmon, I. R., O’Neil, J. J., Burchill, M. A. & Farrar, M. A. STAT5 activation underlies IL7 receptor-dependent B cell development. J. Immunol. 172, 4770–4778 (2004).
pubmed: 15067053
doi: 10.4049/jimmunol.172.8.4770
Dominguez-Sola, D. et al. The FOXO1 transcription factor instructs the germinal center dark zone program. Immunity 43, 1064–1074 (2015).
pubmed: 26620759
doi: 10.1016/j.immuni.2015.10.015
Sander, S. et al. PI3 Kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones. Immunity 43, 1075–1086 (2015).
pubmed: 26620760
doi: 10.1016/j.immuni.2015.10.021
Santos, S. C. et al. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway. Oncogene 20, 2080–2090 (2001).
pubmed: 11360192
doi: 10.1038/sj.onc.1204308
Onishi, M. et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell Biol. 18, 3871–3879 (1998).
pubmed: 9632771
pmcid: 108971
doi: 10.1128/MCB.18.7.3871
Frismantas, V. et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129, e26–e37 (2017).
pubmed: 28122742
pmcid: 5356455
doi: 10.1182/blood-2016-09-738070
Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041–6051 (2009).
pubmed: 19884523
pmcid: 4979100
doi: 10.1200/JCO.2009.25.0779
Bradeen, H. A. et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332–2338 (2006).
pubmed: 16772610
pmcid: 1895563
doi: 10.1182/blood-2006-02-004580
Shojaee, S. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22, 379–387 (2016).
pubmed: 26974310
pmcid: 5178869
doi: 10.1038/nm.4062
Hixon, J.A., et al. New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia 34, 35–49 (2019).
Tummers, B. & Green, D. R. Caspase-8: regulating life and death. Immunol. Rev. 277, 76–89 (2017).
pubmed: 28462525
pmcid: 5417704
doi: 10.1111/imr.12541
Biondi, A. et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 13, 936–945 (2012).
pubmed: 22898679
pmcid: 3431502
doi: 10.1016/S1470-2045(12)70377-7
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
pubmed: 17151364
doi: 10.1056/NEJMoa062867
Ribeiro, D. et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2, 2199–2213 (2018).
pubmed: 30185437
pmcid: 6134214
doi: 10.1182/bloodadvances.2018021063
Ge, Z. et al. Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction. Oncotarget 7, 46014–46027 (2016).
pubmed: 27322554
pmcid: 5216778
doi: 10.18632/oncotarget.10014
Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
doi: 10.1038/nature06866
pubmed: 18408710
Churchman, M. L. et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell 28, 343–356 (2015).
pubmed: 26321221
pmcid: 4573904
doi: 10.1016/j.ccell.2015.07.016
Appelmann, I. et al. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood 125, 1444–1451 (2015).
pubmed: 25499760
pmcid: 4342356
doi: 10.1182/blood-2014-09-601062
Singh, H. et al. A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia. J. Biomol. Screen 19, 158–167 (2014).
pubmed: 23989453
doi: 10.1177/1087057113501081
Dorsey, J. F. et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16, 1589–1595 (2002).
pubmed: 12200668
doi: 10.1038/sj.leu.2402678
Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005–1015 (2014).
pubmed: 25207766
pmcid: 4191900
doi: 10.1056/NEJMoa1403088
von Freeden-Jeffry, U. et al. Lymphopenia in interleukin (IL)−7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J. Exp. Med. 181, 1519–1526 (1995).
doi: 10.1084/jem.181.4.1519
Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 20, 394–397 (1998).
pubmed: 9843216
doi: 10.1038/3877
Belarif, L. et al. IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates. Nat. Commun. 9, 4483 (2018).
pubmed: 30367166
pmcid: 6203796
doi: 10.1038/s41467-018-06804-y
Ellis, J. et al. Anti-IL-7 receptor alpha monoclonal antibody (GSK2618960) in healthy subjects—a randomized, double-blind, placebo-controlled study. Br. J. Clin. Pharmacol. 85, 304–315 (2019).
pubmed: 30161291
doi: 10.1111/bcp.13748
Huber, W. et al. Orchestrating high-throughput genomic analysis with bioconductor. Nat. Methods 12, 115–121 (2015).
pubmed: 25633503
pmcid: 4509590
doi: 10.1038/nmeth.3252
R Core Team. R: a language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria, 2015).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517
pmcid: 16199517
doi: 10.1073/pnas.0506580102
Levit-Zerdoun, E. et al. Survival of igalpha-deficient mature B cells requires BAFF-R function. J. Immunol. 196, 2348–2360 (2016).
pubmed: 26843325
doi: 10.4049/jimmunol.1501707
Krause, S. et al. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood 125, 820–830 (2015).
pubmed: 25428221
doi: 10.1182/blood-2014-06-583062
Alsadeq, A. et al. Effects of p38alpha/beta inhibition on acute lymphoblastic leukemia proliferation and survival in vivo. Leukemia 29, 2307–2316 (2015).
Alsadeq, A. et al. The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. Haematologica 102, 346–355 (2017).
pubmed: 27686375
pmcid: 5286942
doi: 10.3324/haematol.2016.147744
Kohler, F. et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 29, 912–921 (2008).
pubmed: 19084434
doi: 10.1016/j.immuni.2008.10.013
Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210 (2002).
pubmed: 11752295
pmcid: 99122
doi: 10.1093/nar/30.1.207